TrialBMC nephrology2025

Plasma proteome signatures of ASK1 inhibition by selonsertib associate with efficacy in the MOSAIC randomized trial for diabetic kidney disease.

Vladimir Petrovic et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.